GCA
NKTR icon

Gideon Capital Advisors’s Nektar Therapeutics NKTR Stock Holding History

Gideon Capital Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-783
Closed -$145K – 474
2016
Q4 		$145K Buy
+783
New +$159K 0.09% 383

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Gideon Capital Advisors's NKTR Position: Q1 2017 in Review

Gideon Capital Advisors sold out of Nektar Therapeutics (NKTR) in Q1 2017, closing a stake of 783 shares — an estimated $145K sold.

Gideon Capital Advisors first reported a position in NKTR in Q4 2016 and held it in 1 quarter. The position peaked at $145K in Q4 2016. 201 funds tracked by Wall St. Rank hold NKTR as of Q1 2017.

  • Gideon Capital Advisors reported no remaining Nektar Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Gideon Capital Advisors sold 783 Nektar Therapeutics shares in Q1 2017, an estimated $145K.
  • Gideon Capital Advisors first reported a position in Nektar Therapeutics in Q4 2016 and held it in 1 quarter.
  • Gideon Capital Advisors's Nektar Therapeutics position peaked at $145K in Q4 2016.
  • 201 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2017.

Based on Gideon Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.